CNSP News and Press, CNS Pharmaceuticals Inc. From 07/18/22

A new study has found an alternative approach that would make immunotherapy treatments more effective when treating brain tumors. Immunotherapy drugs are usually used to treat a range of cancers. However, glioblastoma multiforme, which is a fatal type of cancer, remains resistant to this r...

Novel brain cancer drug developer CNS Pharmaceuticals, Inc. has received approval from the U.S. FDA for a Protocol Amendment that expands patient eligibility for participation in its potentially pivotal Phase 2 clinical trial for a novel drug candidate that targets the nearly 100 percent ...

Diagnosing brain tumors in a timely manner can be difficult. Early symptoms of the deadly condition, such as coordination problems and persistent headaches, are common to several other medical conditions. Brain tumor diagnosis usually relies on magnetic resonance imaging (MRI) to spot ...

Traditionally, brain tumors are diagnosed by computer topography scans (CT), magnetic resonance imaging (MRI) or a neurologic exam. However, researchers from the Karl Landsteiner University for Health Sciences (KL Krems) have now discovered a more precise and accurate way of diagnosing b...

CNS Pharmaceuticals (NASDAQ:CNSP) is trading 36% higher said on Thursday it had received approval from the U.S. Food and Drug Administration for its ongoing global study testing the efficacy and safety of Berubicin compared with chemotherapy drug Lomustine to treat recurrent gl...

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM PR Newswire Expanded eligibility for patients who have received multiple therapies as first line therapy...

A recent survey presented at the recent International Symposium on Pediatric Neuro-Oncology (ISPNO) suggests that healthcare workers have some knowledge gaps when it comes to central nervous system (CNS) tumors in children. For their study, researchers from... Read more » NOT...

Data shows that at least 700,000 Americans are currently living with brain tumors. However, experts say the average person has less than a 1% chance of developing brain cancer or spinal cord tumor, with the main risk factors being radiation exposure, family history, seizures, and expos...

Glioblastoma is one of the most lethal and common primary brain tumors in adults, with a median survival period of about 15 months post diagnosis. New research has found that glioblastoma may originate from stem cells that aren’t in the same region as the tumors it causes. Unlike ...

CNS Pharmaceuticals (NASDAQ: CNSP) Scientific Advisory Board member Sigmund Hsu, MD, presented at the American Society of Clinical Oncology  (“ASCO”) annual meeting. Hsu’s presentation focused on the company’s ongoing clinical trial evaluating Berubicin for...